11Apr/14

Emerging therapies for relapsed/refractory CLL/SLL expected to offer efficacy … – The Pharma Letter


The Pharma Letter
Emerging therapies for relapsed/refractory CLL/SLL expected to offer efficacy
The Pharma Letter
It is expected that these agents will be added to rituximab-containing regimens, such as bendamustine (Teva Pharmaceutical Industries’ Treanda, Mundipharma’s Ribomustin/Levact, Symbio Pharmaceuticals/Eisai’s Treakisym) in combination with rituximab, …